Clinical benefit rates of 32% were found in two phase III studies with fulvestrant treatment of patients with advanced disease after progression on a non-steroidal AI (51,52), supporting that ER may also be an important driver of metastatic breast cancer cells in patients relapsing from AI therapy. The gene discussed is ESR1; the disease is breast cancer.